Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotech company focused on developing targeted genetic medicine therapies, is set to host an investor webinar on July 24, 2025, at 4:15 p.m. ET. The webinar, led by CEO Eric Poma, Ph.D., will spotlight the company's RedTail(TM) platform, a systemically delivered viral therapy aimed at treating metastatic tumors by evading immune detection. Preclinical data on the lead candidate, CLD-401, has demonstrated tumor elimination and immune memory activation, marking a significant step forward in the fight against cancer.
The company is advancing toward an Investigational New Drug (IND) filing and is actively seeking strategic pharmaceutical partnerships to support the commercialization of its innovative therapies. The webinar will include a presentation followed by a Q&A session, offering investors and stakeholders a deeper understanding of Calidi's groundbreaking work in immuno-oncology. For more details, visit https://ibn.fm/zIp8d.
Calidi Biotherapeutics' approach utilizes novel stem cell-based platforms capable of carrying payloads of oncolytic viruses, targeting high-grade gliomas and solid tumors. Its clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to enhance efficacy and improve patient safety, offering a promising avenue for treating or even preventing metastatic disease.
